Skip to main content
PLOS One logoLink to PLOS One
. 2025 May 13;20(5):e0323651. doi: 10.1371/journal.pone.0323651

Differences in COVID-19 testing perceptions among caregivers of children with medical complexity by rurality

Kristina Devi Singh-Verdeflor 1,*, Michelle M Kelly 1, Gregory P DeMuri 1, Gemma Warner 1, Sabrina M Butteris 1, Mary L Ehlenbach 1, Barbara Katz 2, Joseph A McBride 1,3, Shawn Koval 4, Ryan J Coller 1
Editor: Abdulaziz T Bako5
PMCID: PMC12074607  PMID: 40359415

Abstract

Background

COVID-19 testing safeguards the health of children with medical complexity (CMC) through several key mechanisms, such as the implementation of clinical action plans and COVID-19-directed therapies. However, testing utility is limited by barriers to access and perceptions surrounding use. This study investigated associations between rurality and COVID-19 testing access, intent, motivators, and concerns for caregivers of CMC.

Methods

We conducted a cross-sectional survey (April – June 2022) of English- and Spanish-speaking caregivers of children with at least one complex chronic condition between ages 5–17 at an academic medical center in the Midwestern USA. Rurality was dichotomized using Rural-Urban Commuting Area codes. Outcomes represented COVID-19 testing access, intent, motivators, and concerns. Covariates included demographic and clinical characteristics. Unadjusted and adjusted logistic regression analyses examined associations between rurality and each outcome.

Results

Among 1,432 responses (response rate 49%), 359 (25%) were classified as rural. Respondents had varied education, income, and insurance levels. In the multivariable models, rural and urban caregivers reported similarly high testing access, but rural caregivers had significantly less testing intent (adjusted Odds Ratio [95% CI]: 0.53, [0.40, 0.71]). Notably, rural caregivers were significantly more likely to indicate “It will be difficult to get needed healthcare if my child has it” (2.49 [1.19, 5.18]).

Conclusions

While rural and urban CMC caregivers reported generally high access and ease of COVID-19 testing, potentially modifiable factors exist to improve testing intention and decrease barriers, including communication regarding testing utility and timing as well as access to effective treatment response upon testing positive.

Introduction

COVID-19 testing stands as an invaluable tool in long-term pandemic management, optimizing the health outcomes and well-being of children with medical complexity (CMC) [1]. For CMC, defined as children with complex chronic medical conditions causing severe functional limitations, consistent access to testing facilitates early detection and symptom monitoring, implementation of clinical action plans, and consideration of COVID-19–directed therapies [2,3]. However, the utility of COVID-19 testing is limited by barriers to access and perceptions surrounding use [4–8].

Early in the pandemic, CMC were three times more likely to experience severe illness and eight times more likely to be hospitalized for COVID-19 compared to the general pediatric population, while also encountering decreased access to vital health services [9,10]. For rural CMC and their caregivers, these pandemic-era challenges exacerbated the long-standing gaps in rural healthcare access and quality [11]. Compared to CMC in non-rural environments, rural CMC experience higher rates of emergency department visits and lower rates of primary care and medical specialty visits, suggesting disparities in access to care and unmet health needs [12,13]. Prior research has further demonstrated worse access to COVID-19 testing for rural populations, often stemming from an absence of accessible testing locations, financial constraints, or misinformation [4–8]. Despite the known inequities faced by children living at the intersection of rurality and medical complexity, this continues to be a crucial but under-researched domain.

Our objective was to investigate associations between rurality and COVID-19 testing access, intent, motivators, and concerns for caregivers of CMC. By better understanding rural-urban differences in COVID-19 testing perceptions, clinicians, researchers, and policymakers can effectively target modifiable factors to enhance testing uptake. Further, by using this research to investigate why urban-rural disparities exist, we can design more effective and equitable public health and policy responses to mitigate pathogen transmission in future pandemics, especially for CMC living in both urban and rural communities.

Methods

Study design, setting, and participants

We conducted a cross-sectional analysis of survey data collected from April 1, 2022 - June 30, 2022 at an academic medical center in the Midwestern region of the United States, as part of the National Institutes of Health’s Rapid Acceleration of Diagnostics-Underserved Populations (NIH’s RADx-UP) return-to-school initiative [14]. Survey content was derived from the NIH’s RADx-UP Common Data Elements library [15].

Eligible respondents were English- or Spanish-speaking primary caregivers of children aged 5–17 years with school attendance before March 2020, at least two encounters at our medical center in 2020, and at least one complex chronic condition (CCC), defined as a medical condition expected to last at least 12 months and involve several different organ systems severely enough to require specialty care and probable hospitalization at a tertiary care center [16]. All participants identified as eligible via the electronic health record were invited to participate through web and mail surveys.

As our study focused on children with medical complexity and included socially vulnerable populations, such as non-English speakers, we took measures to mitigate any risk posed to participants. Consent information and study materials were written in plain language and translated into Spanish, and participation was limited to adult parents or guardians via mailed surveys. At our institution, certified Spanish translators reviewed and translated all items, with a second translator performing back-translation and verification to ensure accuracy and consistency. Written consent was obtained by mail and the study was approved by the university’s institutional review board. Results were reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

Outcomes

The outcomes represented COVID-19 testing access, intent, motivators, and concerns. Testing access and intent variables were presented as statements (e.g., “It is easy for my child to get tested for COVID-19.”) with agreement collected on a 5-point Likert scale. Responses were dichotomized as 1 = “Strongly agree” or “Agree” and 2 = “Neither agree nor disagree,” “Disagree,” or “Strongly disagree.”

Additionally, testing motivators (e.g., “Reduce worry that my child has COVID-19”) and concerns (“My child may experience discomfort from being tested”) were presented as responses to the questions “How much do the following [encourage/discourage] you to get your child tested?” Agreement was indicated on a 5-point scale and dichotomized as 1 = “Very much” or “Moderately” and 2 = “Somewhat,” “Slightly,” or “Not at all.”

Primary exposure

Rurality was defined using participant zip code matched to the Rural-Urban Commuting Area (RUCA) codes, which accounts for measures of population density, urbanization, and daily commuting [17]. Rural residence was defined as RUCA levels 4–10 (Isolated Rural Area, Small town, and Micropolitan) and urban residence as RUCA levels 1–3 (Metropolitan) [18].

Covariates

Covariates were selected a priori and included demographic and clinical variables consistent with prior research and suspected to have associations with rurality status and the study outcomes [19,20]. Demographic covariates included caregiver education level, family annual income, health insurance type (private, public and/or private, none), language spoken at home (English or language other than English), and child age (5–10, 11–13, or ≥ 14). Clinical variables included the number of CCCs (1 or ≥ 2), perceived severity of COVID-19 on child’s health, and number of hospital encounters in 2020 (0 or ≥ 1). As previous studies have demonstrated disparities in healthcare access resulting from systemic and structural racism [12,21], we considered race and ethnicity as a covariate, though it was not included in the final models due to missingness and model non-convergence.

Analysis

Summary statistics described respondents’ demographic and clinical characteristics. Univariable followed by multivariable logistic regression models estimated associations between rurality and COVID-19 testing intent, access, motivators, and concerns. Covariates with statistically significant associations were included in the multivariable models, as were those included from prior research regardless of statistical significance [19,20]. Model diagnostics were conducted to assess model fit and stability. Unadjusted and adjusted odds ratios (aOR) are reported. To investigate the potential influence of response bias, we conducted a sensitivity analysis using Chi-squared tests to assess differences between respondents and nonrespondents based on available data from the creation of the eligible cohort. Analyses were conducted in SAS software v.9.4 (SAS Institute, Cary, NC). P-values < .05 were considered statistically significant.

Results

Participants

Among 2,897 eligible caregivers, 1,432 returned surveys (response rate 49%). Overall, 359 (25%) were classified as rural (Table 1). Rural caregivers were significantly more likely to have lower household annual income and caregiver educational attainment, while urban caregivers were significantly more likely to have private insurance for their child and speak a language other than English.

Table 1. Demographic and clinical characteristics of caregivers and children overall and by rurality status1.

All
n (%)
Rural
n (%)
Urban
n (%)
p-value2
Total, n (row %) 1432 (100) 359 (25) 1073 (75)
Caregiver Characteristics
Age
 Median (IQR) 43 (39 - 48) 41 (37 - 46) 43 (39 - 48) <.0001
Parent Race and Ethnicity
 White, Non-Hispanic 1205 (84) 322 (90) 883 (82) 0.0002
 Hispanic 78 (5) 8 (2) 70 (7)
 Black, Non-Hispanic 24 (2) 2 (0.5) 22 (2)
 Other race, Non-Hispanic 47 (3) 4 (1) 43 (4)
 Multiracial, Non-Hispanic 14 (1) 2 (0.5) 12 (1)
 Not reported 64 (5) 21 (6) 43 (4)
Primary Language
 English 1239 (87) 321 (90) 918 (86) 0.0090
 Other 144 (10) 23 (6) 121 (11)
 Missing 49 (3) 15 (4) 34 (3)
Caregiver Highest Education
 < 12th Grade 33 (2) 12 (3) 21 (2) <.0001
 GED or Some College 496 (35) 163 (45) 333 (31)
 Bachelor’s Degree 481 (33) 109 (30) 372 (35)
 Advanced Degree 367 (26) 59 (17) 308 (29)
 Missing 55 (4) 16 (5) 39 (3)
Family Annual Income
 <$35,000 161 (11) 51 (14) 110 (10) <.0001
 $35,000 - $49,999 100 (7) 37 (10) 63 (6)
 $50,000 - $74,999 188 (13) 63 (18) 125 (12)
 $75,000 - $99,999 204 (14) 58 (16) 146 (14)
 > $100,000 577 (41) 79 (22) 498 (46)
 Not Reported 202 (14) 71 (20) 131 (12)
Child Characteristics
Sex
 Male 729 (51) 184 (51) 545 (51) 0.17
 Female 649 (45) 157 (44) 492 (46)
 Non-binary 3 (0) 0 (0) 3 (0)
 Missing/ Not reported 51 (4) 18 (5) 33 (3)
Age
 5 - 10 years old 466 (32) 127 (36) 339 (32) 0.45
 11 - 13 years old 332 (23) 80 (22) 252 (23)
 > 14 years old 625 (44) 151 (42) 474 (44)
 Missing 9 (1) 1 (0) 8 (1)
Primary Insurance Type3
 Public Insurances 522 (36) 173 (48) 349 (33) <.0001
 Private Insurances 866 (61) 169 (47) 697 (65)
 Other Insurances 44 (3) 17 (5) 27 (2)
Number of Complex Chronic Conditions
 1 1021 (71) 235 (65) 786 (73) 0.0047
 2 or more 411 (29) 124 (35) 287 (27)
Hospital Admissions in 2020
 0 1177 (82) 286 (80) 891 (83) 0.15
 1 or more 255 (18) 73 (20) 182 (17)
Ever Tested Positive for COVID-19
 Yes 489 (34) 132 (37) 357 (33) 0.03
 No 840 (59) 188 (52) 652 (61)
 Missing 103 (7) 39 (11) 64 (6)
Perceived likelihood of severe COVID-19 health effects4
 Not at all 480 (34) 100 (28) 380 (36) 0.03
 A little, Somewhat 756 (53) 207 (58) 549 (51)
 Very, Extremely 190 (13) 50 (14) 140 (13)
 Missing 6 (0) 2 (0) 4 (0)

1Rurality is categorized using the Rural-Urban Continuum Area codes, where rural = isolated rural area, small town, and micropolitan; and urban = metropolitan.

2Differences between rural and urban participants were assessed using T-tests, Chi-square tests, and Fisher’s exact tests as appropriate.

3The ‘Public Insurances’ category includes participants with both public and private insurance. The ‘Other Insurances’ category includes participants who selected “Does not have health insurance”, “Don’t Know”, or “Prefer not to answer.”

4Respondents are asked “If your child was sick with COVID-19, how likely would their health be severely affected?”

Rural and urban children were similar regarding sex and age, but rural children were significantly more likely than urban children to have two or more complex chronic conditions (p = 0.005). Rural caregivers were also significantly more likely than urban caregivers to perceive their child as being at risk of severe health effects from COVID-19 (p = 0.03).

Respondents and non-respondents exhibited similar distributions of child age, number of CCCs, and rurality status. However, a greater proportion of respondents identified as non-Hispanic White and reported private insurance use as compared to non-respondents (S1 Table).

Testing intent and access

In the multivariable models (Table 2), rural and urban caregivers reported similar, notably high, testing access: “I know where I can get COVID-19 testing for my child in our community” (94% and 94%, respectively) and “It is easy for my child to get tested for COVID-19” (83% and 84%, respectively). However, rural caregivers were significantly less likely to “get my child tested as often as needed” compared to urban caregivers (aOR [95% CI]: 0.53 [0.40, 0.71]).

Table 2. Frequencies and unadjusted/adjusted associations of COVID-19 testing access and intent with rurality status among caregivers of children with medical complexity1.

Frequency Unadjusted Adjusted2
Rural
n (%)
Urban
n (%)
OR 95% CI p-value OR 95% CI p-value
Testing Access
 I know where I can get COVID-19 testing for my child in our community. 336 (94) 1009 (94) 1.03 (0.61, 1.73) 0.91 0.97 (0.56, 1.69) 0.92
 It is easy for my child to get tested for COVID-19. 294 (83) 900 (84) 0.89 (0.64, 1.22) 0.45 0.92 (0.65, 1.30) 0.63
Testing Intent
 I plan to get my child tested as often as needed. 218 (61) 805 (75) 0.52 (0.40, 0.67) <.0001* 0.53 (0.40, 0.71) <.0001*

1Testing access and intent are collected on a 5-point Likert scale and are dichotomized by 1 = Agree, Strongly agree; 2 = Neither agree nor disagree, Disagree, Strongly disagree.

2Covariates include caregiver education level, family annual income, health insurance coverage type, household primary language, child age, number of complex chronic conditions, perceived severity of COVID-19, and number of hospital encounters in 2020.

*

Statistically significant difference determined by logistic regression models, where statistical significance is defined as p < 0.05.

Testing motivators and concerns

Rural caregivers were significantly less likely than urban caregivers to select any of the given motivators as encouraging testing, e.g., to reduce worry, mitigate transmission, facilitate school attendance, or seek early treatment (Table 3). Notably, the largest effect sizes for rural caregivers were “Belief that my child was exposed to someone who has COVID-19” (0.47 [0.36, 0.62]) and “Reduce worry that my child might have COVID-19” (0.55 [0.42, 0.72]). However, testing “to let my child’s school know that they are safe to attend in-person” was the most common motivator for both rural and urban caregivers (64% and 76%, respectively), followed closely by testing “to get my child treated early (if they are positive)” (63% and 71%, respectively).

Table 3. Frequencies and unadjusted/adjusted associations of COVID-19 testing motivations and concerns with rurality status among caregivers of children with medical complexity1.

Frequency Unadjusted Adjusted2
Rural
n (%)
Urban
n (%)
OR 95% CI p-value OR 95% CI p-value
Motivations to test
 Reduce worry that my child might have COVID-19. 171 (48) 688 (65) 0.50 (0.39, 0.64) <.0001* 0.55 (0.42, 0.72) <.0001*
 Belief that my child was exposed to someone who has COVID-19. 177 (50) 716 (67) 0.47 (0.37, 0.61) <.0001* 0.47 (0.36, 0.62) <.0001*
 To know if my child is safe not to give COVID-19 to friends and family. 202 (57) 755 (71) 0.53 (0.41, 0.68) <.0001* 0.56 (0.43, 0.74) <.0001*
 To know if my child is safe not to give COVID-19 to anyone they are around. 204 (58) 759 (71) 0.55 (0.43, 0.70) <.0001* 0.56 (0.43, 0.74) <.0001*
 To let my child’s school know that they are safe to attend in-person. 227 (64) 801 (76) 0.57 (0.44, 0.74) <.0001* 0.59 (0.44, 0.78) 0.0002*
 To get my child treated early (if they are positive). 226 (63) 753 (71) 0.72 (0.56, 0.92) 0.0096* 0.72 (0.55, 0.95) 0.02*
Concerns with testing
 My child may experience discomfort from being tested. 29 (8) 66 (6) 1.33 (0.85, 2.10) 0.22 0.98 (0.59, 1.61) 0.93
 Even if they don’t have it when tested, my child can still get COVID-19 later. 53 (15) 93 (9) 1.81 (1.26, 2.60) 0.0013* 1.35 (0.90, 2.03) 0.15
 My child doesn’t have COVID-19 symptoms so they don’t need to be tested. 94 (26) 258 (24) 1.11 (0.85, 1.46) 0.45 0.92 (0.68, 1.24) 0.58
 If my child is positive, officials will need to contact the people they’ve been in contact with. 50 (14) 94 (9) 1.67 (1.16, 2.41) 0.0062* 1.43 (0.94, 2.18) 0.10
 I don’t want to know if my child has it. 10 (3) 26 (2) 1.15 (0.55, 2.40) 0.72 1.18 (0.49, 2.81) 0.71
 There is not much they can do for my child if they have it. 44 (12) 71 (7) 1.95 (1.31, 2.90) 0.0010* 1.50 (0.96, 2.35) 0.07
 It will be difficult to get needed healthcare if my child has it. 19 (5) 19 (2) 3.07 (1.61, 5.87) 0.0007* 2.49 (1.19, 5.18) 0.02*

1Testing motivations and concerns ask, “How much do the following [encourage/ discourage] you to get your child tested?” and are dichotomized by 1 = Moderately, Very much; 2 = Not at all, Slightly, Somewhat.

2Covariates include caregiver education level, family annual income, health insurance coverage type, household primary language, child age, number of complex chronic conditions, perceived severity of COVID-19, and number of hospital encounters in 2020.

*

Statistically significant difference determined by logistic regression models, where statistical significance is defined as p < 0.05.

Concerns with testing for COVID-19 revolved around procedure discomfort, the value or necessity of testing, and resource accessibility. Rural caregivers were significantly more likely than urban caregivers to indicate that “it will be difficult to get needed healthcare if my child has it” (2.49 [1.19, 5.18]). Overall, the primary concern with testing for rural and urban caregivers was “My child doesn’t have COVID-19 symptoms so they don’t need to be tested” (26% and 24%, respectively), followed by “Even if they don’t have it when tested, my child can still get COVID-19 later.” (15% and 9%, respectively).

Discussion

This study is among the first to quantify COVID-19 testing perceptions among CMC caregivers, demonstrating key differences between rural and urban populations. Although most rural caregivers reported that it was easy to test their child for COVID-19, four-in-ten still indicated that they did not intend to test their child as often as needed, even amidst the observation that rural CMC in this study may have had greater severity of illness. Motivators for testing revolved around early treatment and safe school attendance, while testing concerns hinged on the utility of testing and access to healthcare. This line of research could guide tailored public health messaging and clinical or policy interventions to encourage testing uptake and mitigate health disparities for rural CMC. These insights also signal the need to explore whether similar perceptions exist for rural populations among other transmissible illnesses, such as influenza.

In contrast to prior studies underscoring the barriers rural populations face to COVID-19 testing access, e.g., transportation, cost, or misinformation [5–7], rural and urban caregivers in our study reported similarly high access to COVID-19 testing. We suspect that national and statewide testing programs, which included options to receive free in-home test kits by mail [22], overcame some challenges faced by these communities early in the pandemic. Some CMC caregivers in this sample may have been enrolled in a care coordination program at our institution, which provides interdisciplinary care and care coordination that can translate to better service access [23,24]. In addition, CMC caregivers often have extensive experience with healthcare navigation [25], and rural caregivers of CMC may be more skilled at obtaining COVID-19 tests when needed compared to rural caregivers of children without medical complexity.

It remains notable, however, that one-in-five caregivers, both rural and urban, still indicate challenges testing their child for COVID-19. In adult populations, Collie-Akers et al. similarly recognized that testing access barriers exist for both rural and urban populations, though challenges had distinct origins. For example, transportation constraints for rural populations center on far distances, while, for urban populations, it centers on the reliance of public transportation even for relatively short distances [4,8]. Qualitative research recognizing the complex interaction of barriers and facilitators for CMC caregivers in urban and rural settings could identify targeted or potentially overlapping strategies that improve access to testing for both populations.

Our observation that rural caregivers were significantly less likely than urban caregivers to test their child as often as needed despite relatively high access to COVID-19 testing aligns with existing research. A lack of clarity around testing guidelines is a commonly cited barrier [4–8]. In our sample, a prominent concern for rural caregivers focused on the utility and timing of testing. As CMC are at a higher risk of COVID-19 infection and often have multiple points of contact between school, home nursing, and medical providers, the opportune times to test may be less obvious [26]. To address this challenge, public health messaging could leverage CMC research and caregiver perspectives to encourage testing at high-impact time frames, emphasizing the value of early detection and symptom monitoring, implementation of clinical action plans, and consideration of COVID-19–directed therapies. Coller et al. highlighted the need to incorporate contextual factors in messaging at these pivotal moments (e.g., new school year, increased virulence) to sustain testing enthusiasm in communities [2].

Even though rural caregivers had lower testing intentions, our data did not suggest that they were disregarding COVID-19. For example, almost all reported wanting to know if their child had COVID-19, and rural caregivers were more likely than urban caregivers to state that their child’s health would be severely affected by COVID-19. This raises the question of why rural populations would have lower testing intentions. Our data suggest that an important explanatory variable may be definitive treatment, namely, rural caregivers were more doubtful about their child being able to receive the needed healthcare if diagnosed with COVID-19. In fact, prior research has exemplified barriers to treatment for rural CMC, including challenges accessing pediatricians, specialty providers, and appropriate, informed emergency care in local hospitals [11,27,28]. The simultaneous interaction of financial constraints, navigation of health systems and insurance, and constant decision-making compound these structural barriers [29]. An important clinical and public health implication is that, even with adequate testing access and motivation, uptake may not occur if families do not perceive access to effective responses after a positive test. Therefore, future pandemic planning must recognize that accounting for urban-rural disparities in testing access may be necessary but insufficient. Policies and public health responses to pandemics must also account for distinct motivators and barriers to definitive treatment faced by rural communities.

An important future research direction is determining whether these findings translate to other respiratory illnesses, such as influenza, RSV, or other novel pathogens. This would be imperative in planning responses to future pandemics by guiding the creation of tailored interventions, efficient resource allocation, effective community engagement, and informed policy development [2,30–32]. Further, this line of research reinforces existing evidence documenting health equity disparities within the pandemic response for CMC and their families, underscoring the importance of improving healthcare access and quality to ensure healthy lives and promote well-being for all at all ages [33,34]. As respiratory concerns are among the leading causes of hospital admission for CMC [35], healthcare providers and public health leaders must recognize the unique challenges facing the rural CMC population. Proactive measures should be taken to develop public health strategies that are tailored to respiratory illness testing motivators and designed to mitigate healthcare access barriers.

Several limitations of this study must be considered. Rurality data was obtained using 5-digit postal zip codes matched to RUCA codes. The use of zip code tabulation areas or federal information processing system codes may have improved precision [36]. As this is a single-center study at a Midwestern academic medical center in the USA, results may not be generalizable to other regions or populations. Despite efforts to mitigate selection bias through diverse recruitment methods and survey design, it remains a limitation that may also affect the generalizability of our findings. Survey questions were standardized across all RADx-UP programs and these questions did not distinguish between perceptions of COVID-19 antigen testing or polymerase chain reaction testing. Due to the diversity of over 30 reported household languages, we reported the most common languages (English and Spanish) and aggregated the remaining for analysis, as sample sizes were insufficient for detailed investigation. Other important motivators and concerns experienced by rural populations may not have been measured in our study.

Despite these limitations, our study revealed important differences in COVID-19 testing perceptions among rural and urban CMC caregivers. This study highlights both the need and value of more research with rural CMC. While rural and urban caregivers reported generally high access and ease of COVID-19 testing, opportunity remains to improve testing intention for rural caregivers. Potentially modifiable factors include communication regarding testing access and timing as well as access to effective treatment response upon testing positive. As multiple respiratory illness epidemics persist, collaborative efforts among healthcare providers, policymakers, and public health leaders to address these challenges are vital to optimize health outcomes for rural CMC populations.

Supporting information

S1 Table. Caregiver and child demographic characteristics by response status, n = 3080.

(DOCX)

pone.0323651.s001.docx (16KB, docx)

Abbreviations

CMC

Children with Medical Complexity

RADx-UP

Rapid Acceleration of Diagnostics-Underserved Populations

CCC

Complex Chronic Condition

RUCA

Rural-Urban Commuting Area

Data Availability

Deidentified study data and materials are available through the NIH RADx-UP Data Hub at https://radxdatahub.nih.gov/study/156. DOI: 10.60773/61bs-2j03

Funding Statement

RC was awarded Grant #OT2 HD107558-01 from the Foundation for the National Institutes of Health (https://www.nih.gov/). The funder did not play any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Peeling RW, Heymann DL, Teo Y-Y, Garcia PJ. Diagnostics for COVID-19: moving from pandemic response to control. Lancet. 2022;399(10326):757–68. doi: 10.1016/S0140-6736(21)02346-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Coller RJ, Kelly MM, Howell KD, Warner G, Butteris SM, Ehlenbach ML, et al. In-home COVID-19 testing for children with medical complexity: feasibility and association with school attendance and safety perceptions. Am J Public Health. 2022;112(S9):S878–82. doi: 10.2105/AJPH.2022.306971 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cohen E, Kuo DZ, Agrawal R, Berry JG, Bhagat SKM, Simon TD, et al. Children with medical complexity: an emerging population for clinical and research initiatives. Pediatrics. 2011;127(3):529–38. doi: 10.1542/peds.2010-0910 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bateman LB, Schoenberger Y-MM, Hansen B, Osborne TN, Okoro GC, Speights KM, et al. Confronting COVID-19 in under-resourced, African American neighborhoods: a qualitative study examining community member and stakeholders’ perceptions. Ethn Health. 2021;26(1):49–67. doi: 10.1080/13557858.2021.1873250 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Van Rensburg D, Adams AK, Perez G, Bishop S, Warne T, Hassell L, et al. Factors influencing COVID-19 testing among Native Americans and Latinos in two rural agricultural communities: a qualitative study. Front Public Health. 2023;11:1220052. doi: 10.3389/fpubh.2023.1220052 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.McElfish PA, Purvis R, James LP, Willis DE, Andersen JA. Perceived barriers to COVID-19 testing. Int J Environ Res Public Health. 2021;18(5):2278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Crozier J, Christensen N, Li P, Stanley G, Clark DS, Selleck C. Rural, underserved, and minority populations’ perceptions of COVID-19 information, testing, and vaccination: report from a southern state. Popul Health Manag. 2022;25(3):413–22. [DOI] [PubMed] [Google Scholar]
  • 8.Collie-Akers VL, Ablah E, Landry S, Honn A, Mussulman L, Ricketts M, et al. Understanding barriers to COVID-19 testing among rural and urban populations in Kansas. Am J Public Health. 2022;112(S9):S874–7. doi: 10.2105/AJPH.2022.306978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kompaniyets L, Agathis NT, Nelson JM, Preston LE, Ko JY, Belay B, et al. Underlying medical conditions associated with severe COVID-19 illness among children. JAMA Netw Open. 2021;4(6):e2111182. doi: 10.1001/jamanetworkopen.2021.11182 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pitch N, Davidson L, Mekhuri S, Patel R, Patel S, Ambreen M. Exploring the experience of family caregivers of children with medical complexity during COVID-19: a qualitative study. BMC Pediatr. 2023;23(1):160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bettenhausen JL, Winterer CM, Colvin JD. Health and poverty of rural children: an under-researched and under-resourced vulnerable population. Acad Pediatr. 2021;21(8S):S126–33. doi: 10.1016/j.acap.2021.08.001 [DOI] [PubMed] [Google Scholar]
  • 12.Ming D, Jones K, White M, Pritchard J, Hammill B, Bush C. Healthcare utilization for Medicaid-insured children with medical complexity: differences by sociodemographic characteristics. Matern Child Health J. 2022;26(12):2407–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Arakelyan M, Freyleue SD, Schaefer AP, Austin AM, Moen EL, O’Malley AJ, et al. Rural-urban disparities in health care delivery for children with medical complexity and moderating effects of payer, disability, and community poverty. J Rural Health. 2024;40(2):326–37. doi: 10.1111/jrh.12827 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.RADx-UP [Internet]. RADx-UP. [cited 2023 Dec 5]. Available from: https://radx-up.org/ [Google Scholar]
  • 15.NIH RADx-UP common data elements [Internet]. RADx-UP. [cited 2021 Dec 2]. Available from: https://radx-up.org/learning-resources/cdes/ [Google Scholar]
  • 16.Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14:199. doi: 10.1186/1471-2431-14-199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hart LG, Larson EH, Lishner DM. Rural definitions for health policy and research. Am J Public Health. 2005;95(7):1149–55. doi: 10.2105/AJPH.2004.042432 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Defining Rural Population | HRSA [Internet]. [cited 2024 May 8]. Available from: https://www.hrsa.gov/rural-health/about-us/what-is-rural [Google Scholar]
  • 19.Howell KD, Kelly MM, DeMuri GP, McBride JA, Katz B, Edmonson MB, et al. COVID-19 vaccination intentions for children with medical complexity. Hosp Pediatr. 2022;12(9):e295–302. doi: 10.1542/hpeds.2022-006544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Georgeades C, Vacek J, Thurm C, Hall M, Rangel S, Minneci PC, et al. Association of rural residence with surgical outcomes among infants at US Children’s Hospitals. Hosp Pediatr. 2023;13(8):733–43. doi: 10.1542/hpeds.2023-007227 [DOI] [PubMed] [Google Scholar]
  • 21.Braveman P, Arkin E, Proctor D, Kauh T, Holm N. Systemic and structural racism: definitions, examples, health damages, and approaches to dismantling. Health Aff. 2022;41(2):171–8. [DOI] [PubMed] [Google Scholar]
  • 22.House TW. The White House. Fact Sheet: The Biden Administration to Begin Distributing At-Home, Rapid COVID-19 Tests to Americans for Free; 2022. [cited 2024 Apr 8]. Available from: https://www.whitehouse.gov/briefing-room/statements-releases/2022/01/14/fact-sheet-the-biden-administration-to-begin-distributing-at-home-rapid-covid-19-tests-to-americans-for-free/ [Google Scholar]
  • 23.Conkol KJ, Martinez-Strengel A, Coller RJ, Bergman DA, Whelan E-M. Pediatric hospitalists’ lessons learned from an innovation award to improve care for children with medical complexity. Hosp Pediatr. 2020;10(8):694–701. doi: 10.1542/hpeds.2020-0069 [DOI] [PubMed] [Google Scholar]
  • 24.Klitzner TS, Rabbitt LA, Chang RKR. Benefits of care coordination for children with complex disease: a pilot medical home project in a resident teaching clinic. J Pediatr. 2010;156(6):1006–10. [DOI] [PubMed] [Google Scholar]
  • 25.Allshouse C, Comeau M, Rodgers R, Wells N. Families of children with medical complexity: a view from the front lines. Pediatrics. 2018;141(Supplement_3):S195-201. [DOI] [PubMed] [Google Scholar]
  • 26.Sherby M, Kalb L, Coller R, DeMuri G, Butteris S, Foxe J. Supporting COVID-19 school safety for children with disabilities and medical complexity. Pediatrics. 2022;149(Supplement_2):e2021054268H. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Van Cleave J, Stille C, Hall D. Child health, vulnerability, and complexity: use of telehealth to enhance care for children and youth with special health care needs. Acad Pediatr. 2022;22(2, Supplement):S34-40. [DOI] [PubMed] [Google Scholar]
  • 28.Walling EB, Fiala M, Connolly A, Drevenak A, Gehlert S. Challenges associated with living remotely from a pediatric cancer center: a qualitative study. J Oncol Pract. 2019;15(3):e219–29. doi: 10.1200/JOP.18.00115 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Bristow S, Jackson D, Shields L, Usher K. The rural mother’s experience of caring for a child with a chronic health condition: an integrative review. J Clin Nurs. 2018;27(13–14):2558–68. doi: 10.1111/jocn.14360 [DOI] [PubMed] [Google Scholar]
  • 30.Haroz EE, Kalb LG, Newland JG, Goldman JL, Mast DK, Ko LK, et al. Implementation of school-based COVID-19 testing programs in underserved populations. Pediatrics. 2022;149(Supplement_2):e2021054268G. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Jolliff A, Werner NE, Barton HJ, Howell KD, Kelly MM, Morgen M, et al. Caregiver perceptions of in-home COVID-19 testing for children with medical complexity: a qualitative study. BMC Pediatr. 2022;22(1):533. doi: 10.1186/s12887-022-03550-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Goldman JL, Kalu IC, Schuster JE, Erickson T, Mast DK, Zimmerman K. Building school-academic partnerships to implement COVID-19 testing in underserved populations. Pediatrics. 2023;152(Suppl 1):e2022060352C. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Chen LP, Singh-Verdeflor K, Kelly MM, Sklansky DJ, Shadman KA, Edmonson MB, et al. Disparities in COVID-19 vaccine intentions, testing and trusted sources by household language for children with medical complexity. PLoS One. 2024;19(6):e0305553. doi: 10.1371/journal.pone.0305553 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Reed D, Wolfe I, Greenwood J, Lignou S. Accessing healthcare during the COVID-19 pandemic: a qualitative exploration of the experiences of parents and carers of children with chronic illness to inform future policies in times of crisis. BMC Health Serv Res. 2023;23(1):530. doi: 10.1186/s12913-023-09452-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Russell CJ, Simon TD. Care of children with medical complexity in the hospital setting. Pediatr Ann. 2014;43(7):e157-62. doi: 10.3928/00904481-20140619-09 [DOI] [PubMed] [Google Scholar]
  • 36.Grubesic TH, Matisziw TC. On the use of ZIP codes and ZIP code tabulation areas (ZCTAs) for the spatial analysis of epidemiological data. Int J Health Geogr. 2006;5:58. doi: 10.1186/1476-072X-5-58 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Abdulaziz Bako

19 Dec 2024

PONE-D-24-43670Differences in COVID-19 testing perceptions from caregivers of children with medical complexity by ruralityPLOS ONE

Dear Dr. Singh-Verdeflor,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Abdulaziz T. Bako, MBBS; MPH; PhD

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In the online submission form, you indicated that The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either a. In a public repository, b. Within the manuscript itself, or c. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1:  Thank you for your time and efforts conducting the study. Please consider the following:

1- Improve the abstract section and add a background section

2- Detail financial support received to fund the study

3- Relate the study to global commitment to universal health coverage and SDG3

4- Shed light on the impact of this study on future pandemic planning

5- Detail the rationale of the study

6- Explain the validation process for translated questionnaire and training of interviewers

7- Explain ethical consideration that had been accounted for vulnerable population

8- What are other languages in Table 1

Reviewer #2:  In this paper, the authors conduct a cross-sectional survey of English- and Spanish-speaking primary caregivers of children with chronic conditions at an academic medical center in the Midwest.

The paper reports that, compared to urban caregivers, rural caregivers had significantly less testing intent and were significantly more likely to indicate difficulties in gaining access to needed healthcare. The authors conclude that potentially modifiable factors can improve perceived barriers associated with COVID-19 testing.

Overall, the paper presents a well-developed approach to investigating associations between rurality (and other explanatory variables) and COVID-related outcome variables in rural-urban areas. The research questions explored in this study – if repeated in a number of robust studies – can be of significance for the implementation of public health interventions in times of pandemics and other public health emergencies.

With that in mind, this reviewer has the following to remark:

Introduction

1.1 The introduction section begins with this sentence: “COVID-19 testing is an invaluable tool in long-term pandemic management.[1]”

This way of in-text citation was used throughout the article. It must be noted that references are usually placed before punctuation (e.g., periods, commas, semicolons).

Therefore, it would be prudent to look at reference placement in the entire manuscript and make any necessary adjustments.

1.2 This section is in need of a more compelling rationale that carries greater weight than the one presented here.

Methods

2.1 In the methods section, the authors write, “Survey content was derived from NIH’s RADx-UP Common Data Elements library[15]”

There should be a space between the reference and the text. And there should be a period after the reference.

Please refer to the PLOS style guidelines and format your manuscript accordingly.

2.2 Additionally, transitions between paragraphs can be improved to make the reading smoother and more fluid.

2.3 Another important issue is the sampling technique. The authors have not mentioned what sampling technique they used. It is advisable to specify it for reasons of clarity and because of its impacts on the credibility of their findings.

Discussion

3.1 In this type of studies, the participants (i.e., those who respond to the survey) are more likely to be willing to take part in the study because they may be interested in the topic for a variety of reasons, or simply because they have extra time on their hands.

I wonder if the authors have taken this aspect into consideration.

3.2 The authors state that “almost all reported wanting to know if their child had COVID-19, and rural caregivers were more likely than urban caregivers to state that their child’s health would be severely affected from COVID-19. This raises the question why rural populations would have lower testing intentions.”

Could this observation be partly related to the nature of this study and the point raised in 3.1?

I hope this review is helpful and wish the authors the very best with their research!

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  WEAM BANJAR

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 May 13;20(5):e0323651. doi: 10.1371/journal.pone.0323651.r003

Author response to Decision Letter 1


14 Jan 2025

Thank you for the opportunity to revise and resubmit our manuscript. In the Data Availability section, we have specified the direct location for data accessibility within the NIH RADx Data Hub.

Responses to reviewers have been compiled for each comment in the "Response to Reviewers" document.

Attachment

Submitted filename: Response to Reviewers.docx

pone.0323651.s003.docx (22.2KB, docx)

Decision Letter 1

Abdulaziz Bako

16 Feb 2025

PONE-D-24-43670R1Differences in COVID-19 testing perceptions from caregivers of children with medical complexity by ruralityPLOS ONE

Dear Dr. Singh-Verdeflor,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

1. Please address the reviewer's concern by shortening the abstract section 2. Replace "an academic medical center in the Midwest" in the methods section of the abstract with "an academic medical center in the Midwestern region of the United States" or other expressions indicating that this study was conducted in the United States. 3. Please thoroughly copyedit the manuscript to identify and address typos ("decrease" was written as "decease" in the conclusion section of the abstract.

Please submit your revised manuscript by Apr 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols .

We look forward to receiving your revised manuscript.

Kind regards,

Abdulaziz T. Bako, MBBS; MPH; PhD

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing all comments. However, it might be relevant to shorten the abstract section.

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  WEAM BANJAR

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step.

PLoS One. 2025 May 13;20(5):e0323651. doi: 10.1371/journal.pone.0323651.r005

Author response to Decision Letter 2


4 Mar 2025

Thank you for the opportunity to revise and resubmit this manuscript. All comments have been addressed in the response to reviewers document.

Attachment

Submitted filename: Response to Reviewers 3.4.25.docx

pone.0323651.s004.docx (15.8KB, docx)

Decision Letter 2

Abdulaziz Bako

13 Apr 2025

Differences in COVID-19 testing perceptions among caregivers of children with medical complexity by rurality

PONE-D-24-43670R2

Dear Dr. Singh-Verdeflor,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager®  and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Abdulaziz T. Bako, MBBS; MPH; PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for taking the time to update the manuscript to this version. We appreciate considering reviewers comments.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: Yes:  WEAM BANJAR

**********

Acceptance letter

Abdulaziz Bako

PONE-D-24-43670R2

PLOS ONE

Dear Dr. Singh-Verdeflor,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Abdulaziz T. Bako

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Caregiver and child demographic characteristics by response status, n = 3080.

    (DOCX)

    pone.0323651.s001.docx (16KB, docx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0323651.s003.docx (22.2KB, docx)
    Attachment

    Submitted filename: Response to Reviewers 3.4.25.docx

    pone.0323651.s004.docx (15.8KB, docx)

    Data Availability Statement

    Deidentified study data and materials are available through the NIH RADx-UP Data Hub at https://radxdatahub.nih.gov/study/156. DOI: 10.60773/61bs-2j03


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES